- Lilly’s oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity Eli Lilly and Company
- Eli Lilly’s weight loss pill orforglipron clears its latest trial, paving way for approval CNBC
- Eli Lilly Ready to Seek Obesity Pill Green Light After Study Hits Goals The Wall Street Journal
- Eli Lilly’s weight-loss pill meets target in key diabetes trial Financial Times
- Lilly pill cuts body weight by 10.5% in patients with type 2 diabetes Reuters
Source link
